PSA-membrane antibody conjugate shows promise for treating metastatic castration-resistant, taxane-refractory prostate cancer
SAN FRANCISCO—A “guided missile” approach to treating metastatic, castration-resistant, taxane-refractory prostate cancer demonstrated success at the 2014 ASCO Genitourinary Cancers Symposium. Daniel Petrylak MD of Yale University Medical Center in New Haven CT discussed the clinical potential arising from his …